Liver injury from nonsteroidal anti-inflammatory drugs in the United States

Liver International

Volumn 36, Issue 4, 2016, Pages 603-609

  Schmeltzer, Paul A ^a   Kosinski, Andrzej S ^b   Kleiner, David E ^c   Hoofnagle, Jay H ^c   Stolz, Andrew ^d   Fontana, Robert J ^e   Russo, Mark W ^a  

^a CAROLINAS MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Diclofenac; Hepatotoxicity; Medication; Nonsteroidal

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMLODIPINE; ASPARTATE AMINOTRANSFERASE; BETA INTERFERON; BILIRUBIN; CELECOXIB; CITALOPRAM; CORTICOSTEROID; DICLOFENAC; DOXYCYCLINE; ETODOLAC; IBUPROFEN; MELOXICAM; METFORMIN; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PREDNISONE; PREGABALIN; RANITIDINE; SULINDAC; TIZANIDINE; VALDECOXIB;

ACUTE HEPATITIS; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; BILIRUBIN BLOOD LEVEL; BLOOD CLOTTING DISORDER; CAUCASIAN; CAUSE OF DEATH; CHOLESTATIC HEPATITIS; CHRONIC HEPATITIS; CHRONIC HEPATITIS C; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG WITHDRAWAL; EOSINOPHILIA; EPIDEMIOLOGY; FACE EDEMA; FEMALE; FEVER; FOLLOW UP; HOSPITALIZATION; HUMAN; HUMAN TISSUE; INJURY SEVERITY; JAUNDICE; LIVER BIOPSY; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NONALCOHOLIC FATTY LIVER; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PHENOTYPE; PRESCRIPTION; PROSPECTIVE STUDY; RASH; SEPTICEMIA; STEVENS JOHNSON SYNDROME; TOXIC HEPATITIS; UNITED STATES; URINE COMPOSITION DISORDER; VERY ELDERLY; CHEMICAL AND DRUG INDUCED LIVER INJURY; CLINICAL TRIAL; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROGNOSIS; REGISTER; RISK FACTOR; TIME FACTOR; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMICAL AND DRUG INDUCED LIVER INJURY; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; PROGNOSIS; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; TIME FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84950983526     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13032     Document Type: Article

References (19)

1. Wolfe M, Lichtenstein D, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999; 340: 1888-99.
2. Lichtenstein D, Sygal S, Wolfe M. Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract: the double-edged sword. Arthritis Rheum 1995; 38: 5-18.
3. Goldkind L, Laine L. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience. Pharmacoepidemiol Drug Saf 2006; 15: 213-20.
4. Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005; 42: 481-9.
5. Rostom A, Goldkind L, Laine L. Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients. Clin Gastroenterol Hepatol 2005; 3: 489-98.
6. Garcia Rodriguez L, Perez Gutthann S, Walker AM, Lueck L. The role of non-steroidal anti-inflammatory drugs in acute liver injury. BMJ 1992; 305: 865-8.
7. Fontana RJ, Watkins PB, Bonkovsky HL, et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf 2009; 32: 55-68.
8. Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-34, 1934.e1-e4.
9. Paulose-Ram R, Hirsch R, Dillon C, Gu Q. Prescription and non-prescription analgesic use among the U.S. adult population: results from the third national health and nutritional examination survey (NHANES III). Pharmacoepidemiol Drug Saf 2003; 12: 315-26.
10. Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144: 1419-25.
11. Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-Induced Liver Injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-21.
12. Bjornsson E, Jerlstad P, Bergqvist A, Olsson R. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol 2005; 40: 1095-101.
13. Banks AT, Zimmerman HJ, Ishak KG, Harter JG. Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology 1995; 22: 820-7.
14. Laine L, Goldkind L, Curtis SP, et al. How common is diclofenac-associated liver injury? Analysis of 17, 289 arthritis patients in a long-term prospective clinical trial. AJG 2009; 104: 356-62.
15. Bjornsson E, Talwalkar J, Treeprasertruk J, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010; 51: 2040-8.
16. deAbajo FJ, Montero D, Madurga M, Garcia Rodriguez LA. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004; 58: 71-80.
17. Kishida T, Onozato T, Kanazawa T, Tanaka S, Kuroda J. Increase in covalent binding of 5-hydroxydiclofenac to hepatic tissues in rats co-treated with lipopolysaccharide and diclofenac: involvement in the onset of diclofenac-induced idiosyncratic hepatotoxicity. J Toxicol Sci 2012; 37: 1143-56.
18. Aithal G, Day C. Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Clin Liver Dis 2007; 11: 563-75.
19. Daly AK, Aithal GP, Leathart JB, et al. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 2007; 132: 272-81.